在EGFR-突变的高级NSCLC中,Osimertinib加化学疗法的生存率EGFR-突变的高级NSCLC
Pasi A Jänne1, David Planchard2,3, Kunihiko Kobayashi4
1Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
The New England journal of medicine
|October 17, 2025
概括
与单独使用 osimertinib 相比,一线 osimertinib 加上化疗显著改善了EGFR 突变高级非小细胞肺癌患者的整体存活率. 这种组合疗法显示,不良事件显著增加.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 表皮生长因子受体 (EGFR) 突变是高级非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 奥西默蒂尼布单一治疗是EGFR突变NSCLC的标准第一线治疗方法.
- 之前的研究表明,用 osimertinib 加上化疗改善了无进展生存率.
研究的目的:
- 为了评估一线 osimertinib 加上白金-pemetrexed 化疗与 osimertinib 单一治疗的整体生存益处.
- 在这个患者群体中评估组合治疗方案的安全性和耐受性.
主要方法:
- 一项第三阶段的国际开放性试验 (FLAURA2) 随机选择了557名EGFR突变高级NSCLC患者.
- 患者接受了奥西默蒂尼布加-佩美特雷克斯化疗或奥西默蒂尼布单独治疗.
- 总体存活率是关键的次要终点.
主要成果:
- 平均整体存活时间在 osimertinib 加上白金-pemetrexed (47.5 个月) 与 osimertinib 单疗 (37.6 个月) 的治疗中显著延长.
- 死亡的危险比率为0.77 (95% CI,0.61到0.96;P=0.02).
- 3级或更高的不良事件发生在70%的组合手臂,而单一治疗手臂的不良事件为34%.
结论:
- 第一线 osimertinib 加上白金-pemetrexed 显著改善了EGFR突变高级NSCLC患者的整体存活率.
- 组合疗法与可逆性3级或更高不良事件的风险增加有关.
- 这种疗法为这个患者群体提供了新的治疗选择,平衡了疗效和毒性.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
